Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Genmab A/S ADR (GMAB)

Genmab A/S ADR (GMAB)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Genmab A/S ADR CARL JACOBSENS VEJ VALBY G7 2500 DNK

www.genmab.com Employees: 2,204 P: 45-7020-2728

Description:

Genmab A/S is a biotechnology company. It specializes in development of antibody therapeutics for the treatment of cancer. The company's product pipeline includes DARZALEX(R), Arzerra(R), tisotumab vedotin, enapotamab vedotin, HexaBody-DR5/DR5(R) and DuoBody-CD3xCD20 (R),which are in clinical stage. Genmab A/S is based in Copenhagen V, Denmark.

Key Statistics

Overview:

Market Capitalization, $K 14,869,926
Enterprise Value, $K 12,711,236
Shares Outstanding, K 661,768
Annual Sales, $ 2,392 M
Annual Net Income, $ 631,910 K
Last Quarter Sales, $ 816,600 K
Last Quarter Net Income, $ 186,610 K
EBIT, $ 903,350 K
EBITDA, $ 946,180 K
60-Month Beta 0.99
% of Insider Shareholders 1.54%
% of Institutional Shareholders 7.07%
Float, K 651,577
% Float 98.46%
Short Volume Ratio 0.27

Growth:

1-Year Return -32.63%
3-Year Return -47.77%
5-Year Return -4.67%
5-Year Revenue Growth 399.19%
5-Year Earnings Growth -68.62%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings 0.29 on 11/06/24
Next Earnings Date N/A
Earnings Per Share ttm 1.03
EPS Growth vs. Prev Qtr 31.82%
EPS Growth vs. Prev Year -38.30%
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00%
Most Recent Split 5-1 on 05/01/18

GMAB Ratios

Ratio
Price/Earnings ttm 22.52
Price/Earnings forward 18.06
Price/Earnings to Growth 0.72
Return-on-Equity % 14.64%
Return-on-Assets % 12.37%
Profit Margin % 26.42%
Debt/Equity 0.00
Price/Sales 6.42
Price/Cash Flow 18.71
Price/Book 3.26
Book Value/Share 7.11
Interest Coverage 6.98
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar